Discover the predictive power of 3D liver models engineered for pharma
Drug-induced liver injury (DILI) continues to be a major source of clinical attrition, precautionary warnings, and post-market withdrawal of drugs. 3D InSight™ Human Liver Microtissues demonstrate enhanced liver phenotype, metabolic activity, and stability in a culture not attainable with conventional two-dimensional hepatic models.
They are a proven 3D liver co-culture model of hepatocytes and Kupffer cells, engineered for predicting drug-induced liver injury, providing greater confidence in compound classification, lead prioritization, and reducing the risk of late-stage attrition.
- Double the sensitivity in DILI prediction without sacrificing specificity using an organotypic, metabolically robust, long-lived spheroid model validated with a set of 110 clinically-defined DILI compounds
- Leverage greater mechanistic accuracy using pooled multi-donor primary human hepatocyte (PHH) and Kupffer cell co-cultures, optimized for 14-day long-term in vitro DILI assessment
DILI Prediction Applications
Tier 1: Short-Term
(Max. 7 days)
Screen quickly with high specificity for potential DILI drugs
Tier 2: Long-Term
Ensure highest sensitivity for DILI drugs with long-term exposure
Compare susceptibility of different pre-clinical species to hepatotoxicity
The mechanistically accurate, organotypic biology of 3D InSight™ Liver
Microtissues mirrors that of native liver tissue.
3D InSight™ Liver Microtissues capture responses other in vitro models miss.
Compounds with clinically defined DILI severity (1 severe, 2 high concern, 3 low concern) predicted [+] or missed [-] by 3D InSight™ Human Liver Microtissues and 2D PHH from the same donor lots.
A more predictive, pharma validated DILI model
Genentech and AstraZeneca put 3D InSight™ Human Liver Microtissues to the test against traditional PHH assays, using a set of 110 clinically-defined DILI compounds. The results speak for themselves.